PAIB-SOs-12
PAIB-SOs-12 is a CYP1A1-activated antimitotic prodrug with affinity for human CYP1A1, with a Ki value of 1.2 μM. PAIB-SOs-12 exhibits nanomolar antiproliferative activity in cancer cells expressing CYP1A1, with a selectivity ratio of over 100 against cancer cells that do not express CYP1A1. PAIB-SOs-12 undergoes CYP1A1-mediated N-dealkylation to form the active metabolite PIB-SO, which induces G2/M cell cycle arrest and microtubule disruption, and shows significantly improved stability in rodent liver microsomes compared to its n-butyl analog. PAIB-SOs-12 can be used in breast cancer-related research.
For research use only. We do not sell to patients.
- CAS No.: 1422528-30-0
- Formula: C20H22Cl2N2O4S
- Molecular Weight:457.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
CYP1A1 1.2 μM (Ki) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
50 nM
|
Antiproliferative activity against MCF7 CYP1A1-expressing breast cancer cells assessed as cell growth inhibition incubated for 48 h by sulforhodamine B staining assay.
Antiproliferative activity against MCF7 CYP1A1-expressing breast cancer cells assessed as cell growth inhibition incubated for 48 h by sulforhodamine B staining assay.
|
36780426 |
| HT-1080 | IC50 |
30 nM
Compound: 12
|
Antiproliferative activity against human HT-1080 cells expressing CYP1A1 assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HT-1080 cells expressing CYP1A1 assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 36780426] |
| HT-1080 | IC50 |
5000 nM
Compound: 12
|
Antiproliferative activity against human HT-1080 cells transfected with empty vector assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HT-1080 cells transfected with empty vector assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 36780426] |
| HT-1080 | IC50 |
4570 nM
Compound: 12
|
Antiproliferative activity against human HT-1080 cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HT-1080 cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 36780426] |
| HT-29 | IC50 |
5000 nM
Compound: 12
|
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 36780426] |
| M21 | IC50 |
5000 nM
Compound: 12
|
Antiproliferative activity against human M21 cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
Antiproliferative activity against human M21 cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 36780426] |
| MCF7 | IC50 |
50 nM
Compound: 12
|
Antiproliferative activity against human MCF7 cells expressing CYP1A1 assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells expressing CYP1A1 assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 36780426] |
In Vitro
PAIB-SOs-12 (compound 12) (48 h) potently inhibits the proliferation of MCF7 breast cancer cells expressing CYP1A1, with an IC50 of 50 nM, and exhibits over 100-fold selectivity against CYP1A1-negative HT-29 and M21 cells[1].
PAIB-SOs-12 (65 nM; 48 h) disrupts the microtubule cytoskeleton of MCF7 breast cancer cells expressing CYP1A1[1].
PAIB-SOs-12 (48 h) potently inhibits the proliferation of HT-1080TM A[1] cells expressing CYP1A1, with an IC50 of 30 nM; it exhibits >167-fold and 152-fold selectivity, respectively, compared with CYP1A1-null HT-1080 empty vector cells and wild-type HT-1080 cells[1].
PAIB-SOs-12 (400 nM; 0-60 min) exhibits superior stability in rodent liver, with a half-life of 111 min in mouse liver microsomes (MLMs), 160 min in rat liver microsomes (RLMs), and a sustained half-life of 120 min in human liver microsomes[1].
PAIB-SOs-12 (32-31600 nM; 15 min) exhibits affinity for human CYP1A1, with a competitive inhibition constant (Ki) of 1.2 μM[1].
PAIB-SOs-12 (145 nM; 48 h) induces G2/M cell cycle arrest in MCF7 breast cancer cells expressing CYP1A1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF7 CYP1A1-expressing breast cancer cells
-
Concentration:145 nM
-
Incubation Time:48 h
-
Result:Induced cell cycle arrest in the G2/M phase, with 34% of cells accumulating in this phase, compared to 16% in DMSO-treated control cells.
-
Cell Line:MCF7 CYP1A1-expressing breast cancer cells
-
Concentration:65 nM
-
Incubation Time:48 h
-
Result:Disrupted the microtubule cytoskeleton of MCF7 cells, similar to positive controls CEU-818, CEU-602, and combretastatin A-4.
Chemical Information
-
CAS No. 1422528-30-0
-
Molecular Weight 457.37
-
Formula C20H22Cl2N2O4S
-
SMILES
O=C1N(CCN1CCCCC)C2=CC=C(S(=O)(OC3=CC(Cl)=CC(Cl)=C3)=O)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[1]. Chavez Alvarez AC, et al. Homologation of the Alkyl Side Chain of Antimitotic Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonate Prodrugs Selectively Targeting CYP1A1-Expressing Breast Cancers Improves Their Stability in Rodent Liver Microsomes. Journal of medicinal chemistry. 2023 Feb 23;66(4):2477-2497. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)